Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 6/20 | 0.34 |
| ▸ | CTSS | P25774 | 6/20 | 0.34 |
| ▸ | CTSK | P43235 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014755 | 0.85 | EPHX2 (0.47) | ALDH1A1CTSLCTSSCTSKEPHX2 | |
| SCHEMBL4801077 | 0.85 | EPHX2 (0.47) | ALDH1A1CTSLCTSSCTSKEPHX2 | |
| SCHEMBL4800038 | 0.84 | EPHX2 (0.35) | ALDH1A1CTSLCTSSCTSKEPHX2 | |
| SCHEMBL3020738 | 0.83 | EPHX2 (0.46) | CTSLCTSSCTSKEPHX2 | |
| SCHEMBL4799139 | 0.82 | EPHX1 (0.36) | CTSLCTSSCTSKPARP10 | |
| SCHEMBL4797850 | 0.79 | MME (0.36) | METAP2KMT2ACTSLCTSSCTSK | |
| SCHEMBL4798052 | 0.78 | CTSS (0.38) | CTSLCTSSCTSK | |
| SCHEMBL4800887 | 0.77 | NPC1 (0.39) | KMT2AALDH1A1TDP1EPHX2 | |
| SCHEMBL4799975 | 0.77 | CTSL (0.43) | KMT2AALDH1A1CTSLCTSSCTSK | |
| SCHEMBL4796236 | 0.77 | MAPT (0.45) | ALDH1A1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | METAP2 234/4885KMT2A 4282/4885ALDH1A1 3512/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | METAP2 234/4885KMT2A 4282/4885ALDH1A1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.